Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA

Nicole E. Rich; Mazen Noureddin; Fasiha Kanwal; Amit G. Singal

doi:10.1016/S2468-1253(21)00100-X

Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA

Nicole E. Rich, Mazen Noureddin, Fasiha Kanwal, Amit G. Singal

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	422-424
Number of pages	3
Journal	The Lancet Gastroenterology and Hepatology
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/S2468-1253(21)00100-X
State	Published - Jun 2021

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/S2468-1253(21)00100-X

Cite this

@article{aff224496ae74931aee567263aa35d54,

title = "Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA",

author = "Rich, {Nicole E.} and Mazen Noureddin and Fasiha Kanwal and Singal, {Amit G.}",

note = "Funding Information: MN has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novartis, Novo Nordisk, Allergan, Blade, EchoSens, Fractyl, Terns, OWL, Siemens, Roche Diagnostic, and Abbott; has received research support from Allergan, Bristol Myers Squibb, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Pfizer, Madrigal, Novartis, Shire, Viking{\textquoteright} and Zydus; and is a minor shareholder or has stocks in Anaetos, Rivus Pharma, and Viking. FK reports grants from Merck and Gilead. AGS has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, Glycotest, Bayer, Eisai, Exelixis, Bristol Myers Squibb, AstraZeneca, Genentech, and TARGET-RWE. NER declared no competing interests.",

year = "2021",

month = jun,

doi = "10.1016/S2468-1253(21)00100-X",

language = "English (US)",

volume = "6",

pages = "422--424",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA

AU - Rich, Nicole E.

AU - Noureddin, Mazen

AU - Kanwal, Fasiha

AU - Singal, Amit G.

N1 - Funding Information: MN has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novartis, Novo Nordisk, Allergan, Blade, EchoSens, Fractyl, Terns, OWL, Siemens, Roche Diagnostic, and Abbott; has received research support from Allergan, Bristol Myers Squibb, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Pfizer, Madrigal, Novartis, Shire, Viking’ and Zydus; and is a minor shareholder or has stocks in Anaetos, Rivus Pharma, and Viking. FK reports grants from Merck and Gilead. AGS has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, Glycotest, Bayer, Eisai, Exelixis, Bristol Myers Squibb, AstraZeneca, Genentech, and TARGET-RWE. NER declared no competing interests.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85106266602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106266602&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(21)00100-X

DO - 10.1016/S2468-1253(21)00100-X

M3 - Comment/debate

C2 - 34015351

AN - SCOPUS:85106266602

SN - 2468-1253

VL - 6

SP - 422

EP - 424

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 6

ER -

Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this